After 6 years of saying this guy has to go... hope its not too late.

Fire and pursue NP for fraud:

1) Claw back fraudulent and excessive salary
2) Claw back fraudulent and excessive grants/awards of stock, options and warrants.

And, Scott, as Chairman, you should have the grace and good sense to simply return the excessive salary and awards as you were supposedly reporting to yourself as a C-Level exec and COB. Or face the same claw backs.

VSBLTY partners:
- Anheuser-Busch InBev SA/NV a massive worldwide brand
- WPP a massive worldwide Advertising Agency
- Johnson Controls huge worldwide industrial infrastructure firm
- and then there is Intel.

Interesting article:

The webinar, "The Future of Retail is Getting Personal," will be moderated by Digital Signage Today Editor Kevin Damask and feature panelists Maroun Ishac, director of business development in the retail, banking, hospitality and education division for Intel, David Roth, CEO, The Store–WPP, chairman, BAV Group and Jay Hutton, co-founder, president, CEO and director at VSBLTY.
https://www.digitalsignagetoday.com/resources/the-future-of-retail-is-getting-personal/

https://networkbuilders.intel.com/commercial-applications/vsblty-vector

Dang, $1.38. And I am still here. Still hoping science can win out over poor communications. Confidence in this management remains low. The last interveiws were the same as ones we have seen for 5 years: long lists of "working on it" indications, upcoming regulatory events and always, the inflection point. Ya, inflection seems to be another word for circling what?

Glad I culled 1/2 and put it elsewhere (FYI- put a good chunk in VSBLTY which is is a fun one to watch to see how a good CEO creates & executes plans, partnerships and hires competence). That and crypto NU I sold this morning- just like CYDY - a total crapshoot!!!

GLTA. Hope your not betting mortgage money...

Great little stealth firm that has aligned itself with some very rich "uncles". Been in since $0.14 and I keep buying. Totally stoked to see $1.15SP- and that's only a $208M MC! Applied AI concepts with strong partnership and clear runway ahead... $2B is "vsbl" w/in 12 months, 10B in a few years if not bot out before then by one of the majors they are already in bed with.

Grateful to my fellow shareholders who have the means, opportunity and skill set to take on a proxy fight.

IMHO Oct 28 we see a new BOD and triple the stock price.

3x: SK said contract signed, but there may be NDA provisions keeping the document private at this time over-riding any material disclosure requirements.

If these guys hadn't bumbled Marketing 101 so often before, I'd like to hope they had a joint announcement with the institution teed up. But my doubts run high.

Likely waiting for end of day today as they still have been dealing with those pesky depositions all week.

My read on this is that CYDY's future is bright as they have multiple catalysts for growth:
1. Lots of scientific data coming along well.
2. Good opportunity for regulatory progress.
3. New funding opportunities.

and of course, the core catalyst:

4. New management & BOD that will actually be trusted by major funding sources, regulatory agencies and scientific institutions to act in a business like manner.

Little voice: That going to be a very interesting first date!

In the meantime this sucks for HIV patients but continues demand for therapeutics- J&J HIV vax fails.

A proxy fight gains zero traction unless management and BOD are weak. We all agree $1.30-$1.40 SP is way undervalued for the technical and regulatory assets under management.

The issue is management.

I agree there is great potential, but disagree about switching teams. This is exactly the time to consider a switch- at the annual meeting.

The market is telling us - $1.30/1.40 - that same old management is not going to work. If your telling me this SP is due to shorts or manipulation, then why isn't opposite true as well? Management and bankers should be able to present a compelling growth story that raises the price just as easily.

NASH, CANCER, HIV, COVID? These are all incredible assets. This management team can't seem to create a compelling brand and keep a steady trusted hand on the tiller. As Charlie Brown says: Good Greif.

Yup. I am long on stock too. SP is the score.

I believe new management is absolutely critical if current management cannot bring SP towards $5 by Oct 26. Given their track record, I am skeptical, but heh... I'm from Missouri "Show Me".

Todays 8-K will certainly drive price down Weds. 968k warrants immediately exercisable at $1. dang, they didn't call me to invest. So ya buy for $1, immediate sell and at todays close of 1.29 you sell 1.25 x 1.29 = total of $1.61. 61% 1 day return to insiders at CYDY? And you want to keep this management in place?

From August 31, 2021 through September 7, 2021, CytoDyn Inc., a Delaware corporation (the “Company”), issued in a private placement to accredited investors a total of 3,872,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), together with warrants to purchase a total of 968,000 shares of Common Stock at an exercise price of $1.00 per share. The securities were issued with a combined purchase price of $1.00 per fixed combination of one share of Common Stock and one quarter of one warrant to purchase one share of Common Stock, for total gross proceeds to the Company of $3,872,000. The warrants have a five-year term and are immediately exercisable. Copies of the forms of warrant and subscription agreement are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K. The foregoing summary of the terms of the forms of warrant and subscription agreement is subject to, and qualified in its entirety by, such documents, which are incorporated herein by reference

I am Super Stoked!!! BLA submission plan aligns perfectly! Professional new management just when needed!

If BLA is weeks away from submission then CYDY will have new BOD and management in time to respond to any BLA deficiencies and to drive increased value of the company. (Oh, ya, new BOD candidate Melissa A. Yeager was Vice President of Regulatory Affairs at Gilead Sciences- gotta like them apples.)

I really hope the BLA gets done. I have doubts as the other plans NP & SK executed thus far seem to focus on continuing to rob shareholders with bloated compensation, hiring/firing blunders, negligent/perhaps illegal marketing communications and failed and/or lied about regulatory filings.

Stoked. Turn the page. 63 Days.

Evil: These assertions you make are not true for me, thus are false.

"Everyone here knows the 13D do NOT have shareholders’ best interests in mind. Even their pawns know they aim to screw everyone over."

A. I am here and I believe 13D has shareholders best interest in mind.

B. Who are the pawns? If I am considered "a pawn" then I do not know, much less think, `13D aim to screw anyone over. In fact I think NP & SK as fellow shareholders will benefit handsomely from success of 13D.

The mission is the exactly same as current BOD & management: get LL approved and get LL to market. Current management has failed to execute these goals so far so I am considering the options.

Plans clearly laid out at https://www.advancingll.com
1. Propose a new board of qualified individuals for shareholders to decide on.
2. If they win, replace management
3. Support & guide new management to obtain FDA approval for LL
- all the same technical, regulatory and marketing assets remain in place.
- the clinical trials, lab studies, collaborations and partnerships remain ongoing
- one would hope that an outgoing CEO and BOD, as substantial shareholders, would have both the grace, business sense and fiduciary responsibility to transition to new leadership with continuity and support.

When or when will NP learn not to BS his way through an interview?
Oh, ya! 10/28/2021.

Closet: I concur.

The plans I read about from NP:
More of the same- another trial delayed, BLA delayed, incoherent PR's & CC's. This plan has put stock at $1.30 with a host of serious issues and thus the need for a proxy fight.

The plans I read about from 13D are pretty clear. Say what your gonna do and do it:
1. Replace ineffective BOD
2. Replace ineffective CEO
3. Properly manage the scientific, marketing and financial assets portfolio of CYDY .

Process:
Step 1: BOD replacement has been disclosed;

Step 2: New CEO candidate and BOD negotiations and planning;

Step 3: Detailed plans will become known over the next 70 days as the proxy takes shape to address the known assets and liabilities.

4. Then there will be the challenges of unknown &/or hidden issues the new BOD & CEO finds upon their appointment.

Catalyst: The next 70 days.

This just goes to show that 13D are are smart, tough and experienced business people who know how to get things done.  Knowing how to wield maximum power and influence with well timed articulate communications is a basic tactic of business.

Of course 13D are intentionally hurting management.  They feel management has hurt shareholders.  Welcome to capitalism and a proxy battle.   This is about control of a potential  multi-billion dollar entity. CYDY is being run by what may be dedicated and compassionate scientists, but who lack of business experience and have significantly limited managerial skills sets. Mgmt and BOD have had years to correct these obvious deficiencies and failed to do so.

If management had not already extensively damaged the business reputation of the company in the pharm/med industry, with regulators, the courts and in the stock market, 13D would not have a purpose to exist, nor position to wield power and influence.

71 days.

Thx cs. Very potent, relevant recording. Lalezari was in the room. FDA relationships and the CYDY brand are both in the toilet.

Listen again: http://lalezari.s3.amazonaws.com/lalezari.mp3

The regulatory and marketing communications naivete of NP is astounding. Really too bad, as CYDY has a great drug that he has driven forward for many years.

IMHO: A 13D win on Oct 28 creates a 3x to 5x SP on Oct 29. Big money will come if NP is gone.

The Peter Principle is a concept in management developed by Laurence J. Peter, which observes that people in a hierarchy tend to rise to their "maximum level of incompetence"

72 Days and counting.

The link: Google "wiki" & CEO"

The CEO is the person who is ultimately accountable for a company's business decisions, including those in operations, marketing, business development, finance, human resources, etc.

you win!

I used to be an NP advocate. Now he has hit the Peter Principle level. The day NP steps aside, SP pops 2x/3x. Its not science, its simple business trust. I hope I am proven wrong, somehow, but I just don't see CYDY succeeding with NP at the helm.

There are numerous worthy partners and deep pocket investors and institutions who would love to put serious money and their connections behind CYDY but will not as long as NP is in. He has repeatedly mismanaged corporate resources, trashed the the CYDY & LL brands and is incapable of managing simple corporate communications. (Watch another embarrassingly cringe-worthy and self-inflicting damage event in few minutes).

Then there is NP's proven and repeated ability to put his own greed above the mission of the company. On top of an insane compensation package for a non-profit, have you read the CURRENT settlement documentation on NP & the BOD fraudulently awarding themselves 5% of the company last year? This is not ancient history, this is TODAY. Do the reading, then let's debate the future of trustworthy management and BOD at CYDY. see: https://www.cytodyn.com/investors/notice-to-stockholders

I hope for positive today, but expect the same old.

Help Wanted:

Articulate spokesperson that can string together 3 coherent sentences, can do math and knows what a calendar does. Marketing skills in line with owner of the food cart in parking lot at 1111 Main St Vancouver, WA a bonus.

Apply: https://www.cytodyn.com/

Good Interview

BLA FOR HIV. BLA FOR HIV. BLA FOR HIV.
When will this be filed correctly? What are they waiting for?

Nice real independent data point for CYDY:
Health Canada. LL under review.
https://covid-vaccine.canada.ca/

Nice IP data point to be reminded of: Patent App for LL for Cancer
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2021026028

Now, back to the another data point: 2348 covid deaths in USA yesterday.


CDC@CDCgov: Rates of #COVID19 are increasing across the U.S.

As of March 23, the 7-day average of new cases per day is 56,225. Help stop the spread of COVID-19.

Wear a mask.
Stay 6 feet apart.
Avoid crowds.
Get a vaccine when it’s available to you.

Might still needs some LL, eh?

"Oil hits skids, drops 7% on worsening outlook for coronavirus in Europe"

"Cases in Poland rise 74% in one day as third wave engulfs EU nation"

"Even with vaccination efforts in full force, the theoretical threshold for vanquishing COVID-19 looks to be out of reach."

Kinda hard to take seriously on last statement you when you don't know what state CYDY is in, but agree NP and BOD are a fail.

Highlights from the trial’s data for this critically ill population include the following:

Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo.

Shortened time to recovery: The average length of hospital stay was reduced by 6 days for patients who received leronlimab with ”commonly used COVID-19 treatments,” also referred to as “Standard of Care” or “SoC,” compared to placebo patients who received SoC only, with a statistically significant p-value of 0.005.

Discharge alive: In addition, patients who received leronlimab demonstrated an improved probability of "discharged alive" at Day 28 (28% versus 11%), a 166% better rate than in the placebo group.

CYDY: just keep up the good work! Replace PR for TPS:
https://vimeo.com/152450708

This investor call better be a 12/19/19 call.

JCI looks like a nice qualification- now they just need actual sales!

Buy CYDY. Sell CYDY. Try not to die or kill others in the meantime.

CDC Overview: How to Select, Wear, and Clean Your Mask
https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-face-coverings.html

Wear masks with two or more layers to stop the spread of COVID-19
Wear the mask over your nose and mouth and secure it under your chin
Masks should be worn by people two years and older
Masks should NOT be worn by children younger than two, people who have trouble breathing, or people who cannot remove the mask without assistance
Do NOT wear masks intended for healthcare workers, for example, N95 respirators
CDC does not recommend the use of face shields alone. Evaluation of face shields is ongoing but effectiveness is unknown at this time.
Evaluation of mask and gaiter materials and structure is ongoing.

nice DD Blue

Bamlanivimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of bamlanivimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19

One of these days after trading 11M shares we will see a 5% holder from a real investment firm step up...

Godspeed for cooperation by both the COVID Task Force teams of JB & DT. The new COVID Task Force will be looking at every scientific opportunity to stop this thing. Therefor Leronlimab will have far better visibility and WH & FDA connections.

$1.99

Right next to the store brand pretzels

Fug. Only 247 pt.